Generic Name and Formulations:
Pyridostigmine bromide 5mg/mL; soln for IV inj; contains benzyl alcohol.
Indications for REGONOL:
As a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
Individualize. Give by IV inj. Usual range: 0.1–0.25mg/kg. Give atropine sulfate or equipotent dose of glycopyrrolate immediately prior to or simultaneously with Regonol.
Intestinal or urinary obstruction.
Bronchial asthma. Cardiac dysrhythmias. Electrolyte imbalance. Adrenal cortical insufficiency. Renal impairment. Neonates. Pregnancy (Cat.C).
Concomitant 4-aminopyridine may delay onset. Possible resistance to reversal with antibiotics associated with paralysis (eg, aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate). Recurrent paralysis possible with quinidine. Magnesium salts may enhance neuromuscular blockade and interfere with restoration.
GI upset, increased salivation and bronchial secretions, miosis and diaphoresis, muscle cramps, fasciculation and weakness, rash.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA Fast-Tracks Treatment for Autism Spectrum Disorder
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics